Company News-Bio-Thera Solutions, Ltd.

2026-02-13

• European Commission grants approval for Gotenfia®, a golimumab biosimilar to Simponi® that was developed by Bio-Thera ...

查看详情

02-032026

Bio-Thera and Avalon Pharma Execute Exclusive Commercialization Agreement for BAT3306, a Proposed Keytruda® Biosimilar for Saudi Arabia and MENA

Guangzhou, China/Riyadh, Saudi Arabia – February 3, 2026 – Bio-Thera Solutions (688177:SH; “Bio-Thera”), a commercial-st...
12-122025

Golimumab biosimilar Gotenfia from STADA and Bio-Thera receives positive CHMP opinion

•Positive opinion from European Medicines Agency supports approval for golimumab biosimilar Gotenfia®developed by Bio-Th...
11-102025

Bio-Thera Solutions Expands Partnership with Dr. Reddy’s through an Exclusive Commercialization and License Agreement for BAT2306, a Proposed Biosimilar Candidate to Cosentyx® (Secukinumab), in Southeast Asia

Guangzhou, China; November 10, 2025: Bio-TheraSolutions (688177:SH; “Bio-Thera”), a commercial-stage biopharmaceuticalco...